Extramedullary acute promyelocytic leukemia
β Scribed by Peter H. Wiernik; Roberto De Bellis; Pablo Muxi; Janice P. Dutcher
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 436 KB
- Volume
- 78
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
BACKGROUND.
Extramedullary acute promyelocytic leukemia (APL) is rare, and said to be more common after treatment with all-trans retinoic acid (ATRA) than after any other treatment.
METHODS.
The case of a child with extramedullary relapse of APL after initial treatment with ATRA and that of an adult whose initial treatment was chemotherapy are presented, and the literature on extramedullary relapse of APL is reviewed. RESULTS. Twenty-six patients were identified, including the 2 current patients. Ethnicitg could be determined in 23 patients, 17 of whom were of other than Northern European extraction. The most common sites of extramedullary disease were the skin (15 patients), central nervous system (5 patients), mediastinum (3 patients), and, curiously, gingiva (3 patients). Extramedullary leukemia developed in 19 patients: after treatment with ATRA (6 patients), cytotoxic chemotherapy (12 patients), or both (1 patient), and developed in 7 others before any treatment for leukemia was given. CONCLUSIONS. These data suggest but do not prove that extramedullary APL may occur more frequently after ATRA than other therapy, since ATRA has been available for a relatively short period of time. However, it is clear from the literature that extramedullary APL may occur after chemotherapy or before any treatment.
π SIMILAR VOLUMES
Because extramedullary depositions of APL are uncommon, information concerning the therapeutic Department of Orthopaedics University Ho Λpital H. Mondor role of ATRA in extramedullary disease is insufficient. In their article, Wiernik et al. state that at least one Creteil, France Gaetano Bacci, M.D
## BACKGROUND. Extramedullary involvement is only occasionally observed in patients with acute promyelocytic leukemia (APL) but has been said to occur more frequently after treatment with all-trans retinoic acid (ATRA) than after treatment with cytotoxic drugs. In the literature, 37 well-documented
Nine children with acute promyelocytic leukemia (APL) are presented. This series of children represents 7% of all acute leukemias and 21% of acute myelogenous leukemias seen during the same period at the Red Cross War Memorial Children's Hospital. These figures are much higher than the incidence quo